<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Low-dose versus high-dose fish oil for pain reduction and function improvement in patients with knee osteoarthritis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Chen, Y; Huang, YC; Lu, WW</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>Annals of the Rheumatic Diseases, 2016, v. 75 n. 1, p. e7</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2016</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/234714">http://hdl.handle.net/10722/234714</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>Annals of the Rheumatic Diseases. Copyright © BMJ Publishing Group.; This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Osteoarthritis (OA) is one of the leading generators of musculoskeletal pain and the main cause of disability. It has been considered an inflammatory disease with low grade inflammation affecting the synovium, cartilage and subchondral bone. To date, there is no disease-modifying OA drug. A few studies have evaluated the efficacy of fish oil in the treatment of OA; nevertheless, the effectiveness and precise benefits of fish oil intake in patients with OA are still far from well understood. We read with deep interest a recent article published in this journal by Hill et al, who found significant improvement of OA pain and function after treatment by fish oil, and suggested that the low-dose fish oil group had much better improvement in pain and function at 2 years in comparison to the high-dose one. The authors are congratulated for the excellent findings and we really appreciate the work performed by them; nevertheless, some worthwhile issues need further exploration.

First of all, this study was designed without a placebo treatment group. The placebo control is used to account for the placebo effect, and it is required in a large number of clinical trials. The authors explained that “It was considered unethical to prevent fish oil supplements for 2 years in these participants”. This is understandable. Nevertheless, since the efficacy of fish oil versus placebo in the treatment of knee OA is still unclear, we are not sure whether it is appropriate to conduct a clinical trial without placebo control to examine the anti-inflammatory efficacy of fish oil for knee OA, and to address that the pain scores in this study were ‘comparable to those seen with placebo effect for pain’.

Second, the patient recruitment and completion of this study was not clearly described. The authors stated that some patients in both groups were withdrawn from therapy at Year 1 and Year 2, but not all these withdrawn patients were excluded from study assessment. Additionally, the sample size for analysis at Year 2 in the low-dose group was 85 after 3 patients were withdrawn from 90 patients at Year 1. However, the reasons for these issues were not addressed. These changes may have led to the bias of the results.

Third, the objective of the study was to compare the effects of an anti-inflammatory dose of fish oil with a lower dose of fish oil in knee OA. We fully agree with the authors that the OA joint inflammation can be partly reflected through the evaluation of bone marrow lesions by MRI, but we have no idea why the authors did not use MRI to assess synovitis, which is a hallmark of joint inflammation and closely related to joint pain and function in OA. In addition, the evaluation of proinflammatory cytokines which contribute to OA pathogenesis, such as interleukin 1β and TNFα, was not performed in the study. On the other hand, knee pain was selected as a parameter of OA in other hand, knee pain was selected as a parameter of OA in other studies. It would be interesting to know more details of the surgery and whether the surgery had influenced the pain and the function assessment. Additionally, some other confounders may need to be addressed, such as the exercise type and intensity, occupation, alcohol-drinking status, smoking-status, diabetes mellitus, etc.

We respect the great contributions of the authors and we would also be very interested in the authors’ response regarding the above issues.

Yan Chen, Yong-Can Huang, William W Lu

Faculty of Medicine, Department of Orthopaedics and Rheumatology, The University of Hong Kong, Hong Kong, P.R. China

Department of Orthopaedics Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P.R. China

Orthopedics Research Center, Peking University Shenzhen Hospital, Shenzhen, P.R. China

Correspondence to Professor William W Lu, Ng Chun-Man Professorship in Orthopaedic Bioengineering, The University of Hong Kong, Room 907, Lab Block, 21 Sassoon Road, Hong Kong 990077, Hong Kong; wwl@hku.hk

Contributors All the authors were involved in the study conception and manuscript design, manuscript drafting and revising, and final approval of the submitted version.

Funding The work was supported by Ng Chun-Man Foundation, National Science Foundation of China (NSFC 81270967), Shenzhen Peacock Project and the Research Grant Council of Hong Kong (HKU7149/13E).

Competing interests None declared.

Provenance and peer review Not commissioned; internally peer reviewed.

To cite Chen Y, Huang Y-C, Lu WW. Ann Rheum Dis Published Online First: [please include Day Month Year]. doi:10.1136/annrheumdis-2015-208754

Accepted 12 October 2015

REFERENCES